Page 16«..10..15161718..3040..»

Category Archives: Global News Feed

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Posted: December 25, 2024 at 2:51 am

WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that the 100th commercial RhodoLED® XL Lamp has now been installed in the US market.

The rest is here:
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Posted in Global News Feed | Comments Off on Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Abivax Announces a Change to the Composition of its Board of Directors

Posted: December 25, 2024 at 2:51 am

Abivax Announces a Change to the Composition of its Board of Directors

Read the original post:
Abivax Announces a Change to the Composition of its Board of Directors

Posted in Global News Feed | Comments Off on Abivax Announces a Change to the Composition of its Board of Directors

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD

Posted: December 25, 2024 at 2:51 am

KENSINGTON, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, today announced the initiation of a Phase 2 study (eDREAM; NCT06659549) with GAL-101 eye drops in patients with dry age-related macular degeneration (dry AMD), a leading cause of adult blindness. The randomized, double-blind, placebo-controlled multicenter study will evaluate the efficacy and safety of GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.

Link:
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD

Posted in Global News Feed | Comments Off on Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD

Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

Posted: December 25, 2024 at 2:51 am

HALIFAX, Nova Scotia and SPRING, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Scientists at Dalhousie University in Halifax, and Io Therapeutics, Inc. in Spring Texas, announced today collaborative publication of data from studies demonstrating effectiveness of the RXR agonist compound IRX4204 in reversing demyelination, and functionally restoring movement in the paralyzed legs of mice subjected to an autoimmune-mediated demyelinating model of human multiple sclerosis (MS). The research report titled: “Selective retinoid X receptor agonism promotes functional recovery and myelin repair in experimental autoimmune encephalomyelitis”, G.D.S Kasheke, et al; was published in the December 21, 2024 edition of Acta Neuropathologica Communications.

Originally posted here:
Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

Posted in Global News Feed | Comments Off on Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million

Posted: December 25, 2024 at 2:51 am

WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the initial 6,000,000 common shares on December 19, 2024.

View original post here:
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million

Posted in Global News Feed | Comments Off on Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

Posted: December 25, 2024 at 2:51 am

Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD).

Read the original post:
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

Posted in Global News Feed | Comments Off on Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

Posted: December 25, 2024 at 2:51 am

BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limited’s proposed re-domiciliation from Australia to the United States, under which Neuphoria will become the ultimate parent company of Bionomics Limited, has been implemented today, December 23, 2024 New York time (December 24, 2024 Sydney time).

See the original post here:
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

Posted in Global News Feed | Comments Off on Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

Posted: December 25, 2024 at 2:51 am

- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction -

More:
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

Posted in Global News Feed | Comments Off on Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX??? to 800 Patients with a…

Posted: December 25, 2024 at 2:51 am

• 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025;

Read the original:
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX??? to 800 Patients with a...

Posted in Global News Feed | Comments Off on PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX??? to 800 Patients with a…

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Posted: December 25, 2024 at 2:51 am

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).

Link:
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Posted in Global News Feed | Comments Off on Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Page 16«..10..15161718..3040..»